Antiobesity Activity of Liraglutide on High Fat Diet-Induced Obesity in Wistar Rats

Vinay Kumar

doi:10.19080/crdoj.2017.03.555602

Abstract

Liraglutide is a glucagon like peptide-1 (GLP-1) analogue. GLP-1 is a potent inhibitor of motility and gastric emptying and has also been shown to inhibit gastric acid secretion. The inhibition of gastric emptying leads to decreased food intake and reduced body weight. The aim of the present study was to investigate the antiobesity effect of the Liraglutide on high fat diet (HFD) induced obesity in Wistar rats.

Highlights

Obesity has increased at an alarming rate in recent years and is a worldwide public health problem [1]
Animals were randomly allocated into five groups of six animals each and treated as follows: Normal Control Group: Rats fed with normal rat chow diet for 6 weeks; High Fat Diet Control Group: Rats fed with high fat diet for 6 weeks; Liraglutide Treated Group: Rats fed with high fat diet for 6 weeks+from 29th day Liraglutide (0.2mg/kg, i.p) for 2 weeks; Orlistat Treated Group: Rats fed with high fat diet for 6 weeks+from 29th day Orlistat (10mg/kg, i.p) for 2 weeks; Perse Group: Rats fed with normal chow diet for 6 weeks+from 29th day Liraglutide for 2 weeks
In the present work the anti-obesity activity of Liraglutide on high fat diet induced obesity in Wistar was investigated by analyzing the body mass index (BMI), body weight, organ and fat pad weight and blood biochemical profiles

Summary

Introduction

Obesity has increased at an alarming rate in recent years and is a worldwide public health problem [1]. It is one of the most common nutritional disorders in humans. Obesity results when energy intake exceeds energy expenditure. The global epidemic of obesity is rapidly evolving as one of the major global health issues as it is frequently associated with a number of diseases with high mortality and morbidity such as diabetes, cancer, arthritis, hypertension, stroke, and myocardial infarction [2]. It is generally accepted that the tremendous rise in the obesity prevalence across the globe is driven primarily by a combination of increased calorie intake and decreased physical activity, and strongly influenced by our genetic background [3]. Only two medications-Sibutramine and Orlistat-have been approved for long-term use in the treatment of obesity and additional effective pharmacological treatments are needed [6]

Objectives

Methods

Conclusion